caa a22 4500 469073969 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741146 doi (NATIONALLICENCE)springer-10.1007/BF01741146 Phase I trial of ImuVert (natural membrane vesicles associated with ribosomes) in patients with advanced cancer [Elektronische Daten] [Abraham Mittelman, Richard Urban, George Wong, Tauseef Ahmed, Zalmen Arlin] Summary: ImuVert, a new biological response modifier, was evaluated for toxicity and potential efficacy in patients with advanced cancer. This agent consists of sized, labile, natural membrane vesicles associated with ribosomes derived fromSerratia marcescens. ImuVert induces enhanced in vitro macrophage and natural-killer-cell-mediated cytotoxicity, and has demonstrated antitumor activity in palpable animal tumor systems. A group of 39 patients with a variety of tumors, 25 men, 14 women, with a mean performance status (Karnofsky) of 80% and median age of 57 years were entered into this trial. ImuVert was administered subcutaneously weekly for a minimum of 3 weeks. A total of 183 treatments were evaluated. Flu-like systemic toxicities, including fever, chills, nausea, vomiting, diarrhea and hypotension were observed. Erythema, induration and tenderness developed at the injection sites. Myelosuppression, thrombocytopenia, anaphylaxis, rental and hepatic toxicities did not occur. All symptoms resolved within 24 h. Two patients with nodular lymphoma achieved a partial response and two minor responses were seen in patients with glioblastoma and melanoma. On the basis of ImuVert's biological activity, and tolerable toxicity it warrants further clinical investigation. Springer-Verlag, 1992 Biological response modifiers nationallicence Natural membrane vesicle nationallicence Ribosome nationallicence Serratia nationallicence Mittelman Abraham Division of Neoplastic Diseases, New York Medical College and Westchester County Medical Center, 10595, Valhalla, New York, USA aut Urban Richard aut Wong George Division of Biostatistics, Memorial Sloan-Kettering Cancer Center, 10021, New York, NY, USA aut Ahmed Tauseef Division of Neoplastic Diseases, New York Medical College and Westchester County Medical Center, 10595, Valhalla, New York, USA aut Arlin Zalmen Division of Neoplastic Diseases, New York Medical College and Westchester County Medical Center, 10595, Valhalla, New York, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 331-334 0340-7004 35:5<331 1992 35 262 https://doi.org/10.1007/BF01741146 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741146 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mittelman Abraham Division of Neoplastic Diseases, New York Medical College and Westchester County Medical Center, 10595, Valhalla, New York, USA aut NATIONALLICENCE 700 1- Urban Richard aut NATIONALLICENCE 700 1- Wong George Division of Biostatistics, Memorial Sloan-Kettering Cancer Center, 10021, New York, NY, USA aut NATIONALLICENCE 700 1- Ahmed Tauseef Division of Neoplastic Diseases, New York Medical College and Westchester County Medical Center, 10595, Valhalla, New York, USA aut NATIONALLICENCE 700 1- Arlin Zalmen Division of Neoplastic Diseases, New York Medical College and Westchester County Medical Center, 10595, Valhalla, New York, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 331-334 0340-7004 35:5<331 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer